Evaluation of Proton-Induced DNA Damage in 3D-Engineered Glioblastoma Microenvironments
Qais Akolawala1, Marta Rovituso2, Henri H Versteeg3
1Department of Precision and Microsystems Engineering, Delft University of Technology, Mekelweg 2, 2628 CD Delft, The Netherlands.
Abstract:
Glioblastoma (GBM) is a devastating cancer of the brain with an extremely poor prognosis. For this reason, besides clinical and preclinical studies, novel in vitro models for the assessment of cancer response to drugs and radiation are being developed. In such context, three-dimensional (3D)-engineered cellular microenvironments, compared to unrealistic two-dimensional (2D) monolayer cell culture, provide a model closer to the in vivo configuration. Concerning cancer treatment, while X-ray radiotherapy and chemotherapy remain the current standard, proton beam therapy is an appealing alternative as protons can be efficiently targeted to destroy cancer cells while sparing the surrounding healthy tissue. However, despite the treatment's compelling biological and medical rationale, little is known about the effects of protons on GBM at the cellular level. In this work, we designed novel 3D-engineered scaffolds inspired by the geometry of brain blood vessels, which cover a vital role in the colonization mechanisms of GBM cells. The architectures were fabricated by two-photon polymerization (2PP), cultured with U-251 GBM cells and integrated for the first time in the context of proton radiation experiments to assess their response to treatment. We employed Gamma H2A.X as a fluorescent biomarker to identify the DNA damage induced in the cells by proton beams. The results show a higher DNA double-strand breakage in 2D cell monolayers as compared to cells cultured in 3D. The discrepancy in terms of proton radiation response could indicate a difference in the radioresistance of the GBM cells or in the rate of repair kinetics between 2D cell monolayers and 3D cell networks. Thus, these biomimetic-engineered 3D scaffolds pave the way for the realization of a benchmark tool that can be used to routinely assess the effects of proton therapy on 3D GBM cell networks and other types of cancer cells.
Insights
Novel 3D scaffolds mimic brain blood vessels to study glioblastoma (GBM) response to proton therapy. Results show 3D cell cultures exhibit greater radioresistance than 2D cultures, aiding in developing better cancer treatments.
Area of Science:
- Biomedical Engineering
- Cancer Research
- Radiation Oncology
Background:
- Glioblastoma (GBM) is an aggressive brain cancer with poor outcomes.
- Current 2D cell cultures do not accurately reflect the in vivo tumor microenvironment.
- Proton beam therapy offers targeted cancer treatment with potential for reduced side effects.
Purpose of the Study:
- To develop and evaluate novel 3D-engineered scaffolds for glioblastoma (GBM) research.
- To assess the response of GBM cells in 3D microenvironments to proton radiation.
- To investigate the differences in DNA damage and repair between 2D and 3D GBM cell cultures under proton irradiation.
Main Methods:
- Fabrication of 3D scaffolds using two-photon polymerization (2PP), inspired by brain vasculature geometry.
- Culture of U-251 GBM cells within the 3D scaffolds.
- Irradiation of GBM cells in both 2D and 3D models using proton beams.
- Quantification of DNA double-strand breaks using the Gamma H2A.X biomarker.
Main Results:
- 3D-engineered scaffolds successfully cultured U-251 GBM cells.
- Cells cultured in 3D scaffolds showed significantly less DNA double-strand breakage compared to 2D cell monolayers after proton irradiation.
- This suggests potential differences in radioresistance or DNA repair kinetics between 2D and 3D GBM cell models.
Conclusions:
- Biomimetic 3D scaffolds provide a more relevant in vitro model for studying GBM response to proton therapy.
- These 3D models can serve as a benchmark tool for assessing proton therapy efficacy on cancer cells.
- Further research using these 3D models may lead to optimized proton therapy strategies for glioblastoma and other cancers.


